Jaguar Health announced that the Company has received a Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application No. 16/617,466, titled Methods And Compositions For Treating Bile Acid Diarrhea, Diarrhea Associated With Small Intestine Resection Or Gallbladder Removal, And Short Bowel Syndrome.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on JAGX:
- Jaguar Health reaches 75% enrollement in Phase 3 OnTarget trial of crofelemer
- Jaguar Health announces initial close in private placement financing
- Jaguar Health regains compliance with Nasdaq minimum bid price rule
- Jaguar Health, SynWorld mutually agree to terminate license agreement
- Jaguar Health engages ShareIntel to monitor trading activity